News | January 06, 2026
Nia Therapeutics unveils first implantable brain interface for memory disorders
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
The companies aim to expand treatment options for millions living with metabolic disorders
Akero became a wholly owned subsidiary of Novo Nordisk
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
Subscribe To Our Newsletter & Stay Updated
